PET imaging with [18F]Me-4FDG has provided some interesting complementarity to [18F]FDG. [18F]Me-4FDG shows comparatively low uptake into the kidneys and urinary excretion compared to [18F]FDG due to reabsorption from the glomerular filtrate by SGLTs. Since the blood-brain barrier uses primarily GLUT1 and not SGLTs, [18F]Me-4FDG shows only low brain uptake under normal conditions. This offers an opportunity in cases such as astrocytoma, where [18F]FDG struggles to achieve contrast due to high baseline brain uptake of the tracer. Importantly, the researchers found evidence to support SGLT2 expression in the proliferating tumor microvasculature, suggesting a mechanism for selective uptake. This work was published last year in Journal of Neuro-Oncology (DOI: 10.1007/s11060-018-2823-7).